ENDP
$8.43
Endo Int'l Plc
$.09
1.08%
ENDP
Earnings Whisper ®
N/A
3rd Quarter September 2017
Consensus:  $0.67
Revenue:  $780.75 Mil
Tuesday
Nov 7
6:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Tuesday, August 08, 2017

What do you expect when ENDP reports earnings?
Beat
Meet
Miss

Where is ENDP's stock price going from here?
Up
Flat
Down
Stock chart of ENDP
Analysts
Summary of analysts' recommendations for ENDP
Score
Grade
Pivots
Resistance
$9.18
$8.97
$8.66

$8.45

Support
$8.13
$7.92
$7.61
Tweet
Growth
Description
Endo International plc is a global specialty healthcare company. It develops, manufactures, markets, and distributes quality branded pharmaceutical and generic products as well as medical devices. Endo offers branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel for pain, urology, endocrinology, and oncology. The company also provides non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and hypertension markets. Endo International plc, formerly known as Endo Pharmaceuticals Holdings Inc., is headquartered in Dublin, Ireland.
Peers
Regeneron PharmaceuticalsBioMarin PharmaceuticalCelgeneVertex PharmaceuticalsEli LillyUltragenyx PharmaceuticalZoetisInterCeptJohnson & JohnsonPfizer